• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Aadi Bioscience Closes $23 Million in Series A Funding
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Read More
Caley Castelein, MD
Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa
Read More
Neil Desai, PhD

Comments

Comments are closed.

  • Next Post
  • Previous Post